Here are what the editors at HealthDay consider to be the most important developments in Pain Management for January 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Patient Attitude Tied to Physical Therapy Outcomes
WEDNESDAY, Jan. 30, 2019 (HealthDay News) — Patient expectation and pain self-efficacy are associated with clinical outcomes among patients undergoing physical therapy for shoulder pain, according to a study published online Jan. 24 in the British Journal of Sports Medicine.
Evidence Lacking for Benefit of Surgery for Vertebral Fractures
MONDAY, Jan. 28, 2019 (HealthDay News) — Surgical procedures do not appear to provide significant benefit for patients with vertebral fractures (VF), according to a second American Society for Bone and Mineral Research Task Force report published in the January issue of the Journal of Bone and Mineral Research.
Report IDs Areas Lacking Good Practice in Health Tech Assessment
FRIDAY, Jan. 25, 2019 (HealthDay News) — In a report published in the January issue of Value in Health, an ISPOR–The Professional Society for Health Economics and Outcomes Research working group indicates the lack of good practices in three areas of health technology assessment (HTA).
Marketing of Opioids Linked to Increased OD Mortality
WEDNESDAY, Jan. 23, 2019 (HealthDay News) — Marketing of opioids to physicians is associated with increased mortality from opioid overdoses, according to a study published online Jan. 18 in JAMA Network Open.
Benzodiazepine, Opioid Co-Usage Up in the United States
WEDNESDAY, Jan. 23, 2019 (HealthDay News) — Concurrent use of benzodiazepine receptor modulators and opioids and of nonselective and selective benzodiazepine receptor modulators increased from 1999-2000 to 2013-2014, according to a study published online Jan. 17 in SLEEP.
Medical Cannabis Decisions Being Made by Users, Not Doctors
TUESDAY, Jan. 22, 2019 (HealthDay News) — Many patients use medical cannabis without their mainstream health care provider’s knowledge, and further, they self-adjust their pharmaceutical use in response to cannabis use, according to a study published online Jan. 8 in the Journal of Psychoactive Drugs.
FDA Down to 5 Weeks of Funding to Review New Drug Applications
THURSDAY, Jan. 17, 2019 (HealthDay News) — Due to the federal government shutdown, the U.S. Food and Drug Administration has only about five weeks of funding left to review new drug applications, according to Commissioner Scott Gottlieb, M.D.
Adoption of Advanced Health IT Capabilities Inconsistent